Patient case: 70-year-old female with breast cancer; genetic feature: AURKA amplification

Clinical trial: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Summary: This is an open-label, multi-institution, phase Ib trial that evaluates the safety and tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer.

Detailed description: Primary Objectives
  • To determine the safety and tolerability of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.
  Secondary Objectives
  -  To determine the anti-tumor effect of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.
  -  Pharmacokinetic assessments of erdafitinib
  Correlative Objectives
  -  To determine the therapeutic predictive role of FGFR1-4, CCND1-2, CDK4 and CDK6 amplifications, and RB1 and ESR1 mutations on clinical outcome
  -  To determine if the FGFR1 amplification levels is an early surrogate of response
  -  To determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to CDK4/6 and FGFR inhibition
  -  To determine pharmacodynamic biomarkers of FGFR inhibition

Eligibility: Inclusion Criteria:
  -  Patients must be able to swallow and retain oral medication
  -  Patients must be ≥ 18 years of age
  -  Female patients of no childbearing potential must be post-menopausal. Postmenopausal female subjects should be defined prior to protocol enrollment by any of the following:
  -  Participants at least 60 years of age; OR
  -  Participants under 60 years of age and naturally (spontaneous, no alternative pathologic or physiological cause) amenorrhea for at least 12 months; OR
  -  Medical ovarian failure confirmed by follicle-stimulating hormone (FSH) and estradiol levels in the post menopausal range per local institutional normal range; OR
  -  Prior bilateral oophorectomy; OR
  -  Prior radiation castration with amenorrhea for at least 6 months; OR
  -  Treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (such as goserelin acetate or leuprolide acetate) is permitted for induction of ovarian suppression as long as it has been initiated at least 28 days prior to study enrollment
  -  Patients must have ECOG performance status 0 - 1
  -  Patients must have clinical stage IV or inoperable locoregional recurrent invasive mammary carcinoma that is:
  -  ER+ and/or PgR+ (≥ 1% positive stained cells) by immunohistochemistry (IHC)
  -  HER2-negative (by IHC or FISH, per ASCO guidelines)
  -  FGFR1 - 4 amplified
  -  Patients must have evaluable (may have either measurable or non-measurable) disease
  -  Patients must have available tissue for FGFR determination
  -  Patients must have had at least one line of therapy in the metastatic setting
  -  Current use of any of the drugs listed on the Cautionary Concomitant Med list has to be approved by the Study Chair
  -  Patients must have adequate hematologic, hepatic and renal function. All laboratory tests must be obtained within 2 weeks from study drug initiation. These include:
  -  ANC ≥ 1,500/mm3
  -  Platelet count ≥ 100,000/mm3
  -  HgB ≥ 9.0 g/dL
  -  Creatinine clearance ≥ 40 mL/min/1.73 m2
  -  SGOT, SGPT ≤ 2.5 x ULN if no liver metastasis present; SGOT, SGPT ≤ 4 x ULN if liver metastasis present
  -  Albumin ≥ 2.0 g/dL
  -  Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN if known Gilbert's syndrome)
  -  Potassium within institutional normal limits
  -  Phosphorus ≤ institutional upper limit of normal
  Exclusion Criteria:
  -  Prior use of an FGFR inhibitor
  -  More than 2 lines of chemotherapy in the metastatic setting. No limit on endocrine therapy lines. Prior exposure to CDK4/6 inhibitor acceptable.
  -  Radiation therapy ≤ 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment (except for alopecia)
  -  Prior cancer therapy (except for endocrine therapy) must have been discontinued for 1 week prior to initiation of study drugs
  -  Concurrent anti-cancer therapy other than the ones specified in the protocol is not permitted during study participation. Bisphosphonates or denosumab are allowed
  -  Major surgery within 4 weeks of enrollment
  -  Herbal preparations are not allowed throughout the study, and should be discontinued 14 days prior to initiation of study treatment
  -  Any corneal or retinal abnormality likely to increase the risk of eye toxicity, such as:
  -  Current corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
  -  Uncontrolled glaucoma despite standard of care therapy
  -  Diabetic retinopathy with macular edema
  -  Known active wet, age-related macular degeneration (AMD)
  -  Known central serous retinopathy (CSR) or retinal vascular occlusion (RVO)
  -  Uncontrolled intercurrent illness including, but not limited to:
  -  Malabsorption syndrome significantly affecting gastrointestinal function
  -  Ongoing or active infection requiring antibiotics/antivirals
  -  Impairment of lung function (COPD > grade 2, lung conditions requiring oxygen therapy)
  -  Symptomatic congestive heart failure
  -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
  -  Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [National Cancer Institute -Common Terminology Criteria for Adverse Events, Version 4.03, grade 3]
  -  QTcF ≥ 480 msec on screening EKG
  -  Known history of clinically significant QT/QTc prolongation or Torsades de Pointes(TdP)
  -  ST depression or elevation of ≥ 1.5 mm in 2 or more leads
  -  Diarrhea of any cause ≥ CTCAE grade 2 that does not resolve within a few days when adequately treated with anti-diarrhea medications
  -  Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary
  -  Symptomatic brain metastases (patients with a history of brain metastases must be clinically stable for more than 4 weeks from completion of radiation treatment and be off steroids)
  -  Known history of chronic liver or chronic renal failure
  -  Poor wound healing capacity

Relevance to patient case: not relevant